Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | MAP2 | P11137 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23478373 | 0.87 | HTR6 (0.51) | HTR6ACHEKIF11FEN1MAPK14 | |
| SCHEMBL23452429 | 0.76 | ACHE (0.40) | HTR6ACHEKIF11FEN1MAPK14 | |
| Trifluoroacetic Acid SCHEMBL6066580 | 0.73 | DAO (0.46) | HRH4HRH3LOXL2 | |
| Trifluoroacetic Acid SCHEMBL31704032 | 0.70 | KDM5A (0.60) | ACHEKIF11FEN1PARP1CSNK2A1 | |
| SCHEMBL31558474 | 0.69 | HTR6 (0.51) | HTR6ACHEKIF11FEN1MAPK14 | |
| SCHEMBL23478372 | 0.69 | NAMPT (0.43) | HTR6 | |
| Trifluoroacetic Acid SCHEMBL3614050 | 0.67 | LOXL2 (0.61) | HRH4HRH3LOXL2 | |
| Trifluoroacetic Acid SCHEMBL3973104 | 0.66 | LOXL2 (0.46) | HRH4HRH3MAPTLOXL2 | |
| Picolamine SCHEMBL29881376 | 0.65 | NAPRT (0.54) | — | |
| Trifluoroacetic Acid SCHEMBL2768594 | 0.64 | CHUK (0.46) | KIF11CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | HTR6 4242/4885ACHE 2723/4885KIF11 3394/4885 |
| US-12486278-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | HTR6 4242/4885ACHE 2723/4885KIF11 3394/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | HTR6 4242/4885ACHE 2723/4885KIF11 3394/4885 |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | HTR6 4242/4885ACHE 2723/4885KIF11 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.